Realm Therapeutics PLC Block Listing Application (8780T)
October 18 2017 - 1:00AM
UK Regulatory
TIDMRLM
RNS Number : 8780T
Realm Therapeutics PLC
18 October 2017
Realm Therapeutics plc
("Realm Therapeutics", "Realm" or the "Company")
Block Listing Application
18 October 2017 - Realm Therapeutics plc (AIM: RLM), a clinical
stage biopharmaceutical company focused on leveraging its
proprietary immunomodulatory technology, announces that an
application has been made for the block admission, in aggregate, of
21,139,826 ordinary shares of 10p each in the Company (the "Block
Admission Shares") in relation to certain outstanding, but not yet
exercised warrants. The Block Admission Shares will be available to
be issued as needed to satisfy the valid exercise of the following
warrants:
- 20,898,448 Block Admission Shares in relation to a portion of
the warrants issued in connection with the recent placing to raise
GBP19.3 million ($26 million), as approved by shareholders on 9
October 2017 (the "Placing"); and
- 241,378 Block Admission Shares in relation to a portion of the
warrants issued in December 2013 (and adjusted as a result of the
Placing) in conjunction with the establishment of a credit facility
with the Company's bank, the remainder of which are already subject
to an existing block listing.
This block admission is further to the Company's existing block
listing of ordinary shares of 10p each in connection with the
Company's equity plans and in respect of the warrants issued in
connection with the credit facility.
It is expected that the block admission will become effective on
23 October 2017. When issued, the Block Admission Shares will be
credited as fully paid and will rank pari passu with the existing
ordinary shares of the Company.
Enquiries:
+44 (0) 20 3727
Realm Therapeutics plc 1000
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial
Officer and Chief Operating Officer
+44 (0) 20 3727
FTI Consulting 1000
Simon Conway / Mo Noonan
N+1 Singer (Nominated Adviser +44 (0) 20 7496
and Broker) 3000
Aubrey Powell / Lauren Kettle
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company
focused on developing novel immunomodulatory therapies to protect
and improve the lives of adults and children. The Company has
initiated drug development programmes, based on its proprietary
hypochlorous acid technology at high concentrations. The Company
believes its formulations have novel immunomodulatory activity with
potential application for the treatment of diseases in a number of
therapeutic areas, including Dermatology and Ophthalmology.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSFFMFWWFWSEDS
(END) Dow Jones Newswires
October 18, 2017 02:00 ET (06:00 GMT)
Realm Thera. (LSE:RLM)
Historical Stock Chart
From Apr 2024 to May 2024
Realm Thera. (LSE:RLM)
Historical Stock Chart
From May 2023 to May 2024